BHC - Bausch Health Companies Inc.

NYSE - NYSE Delayed Price. Currency in USD
23.13
+0.08 (+0.35%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close23.05
Open23.08
Bid23.13 x 1000
Ask23.16 x 800
Day's Range22.68 - 23.30
52 Week Range17.20 - 28.45
Volume4,196,401
Avg. Volume4,015,588
Market Cap8.119B
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-11.81
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est30.00
Trade prices are not sourced from all markets
  • Benzingayesterday

    Jim Cramer Shares His Thoughts On AMD, Gilead, Nvidia And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he would wait for Arista Networks Inc (NYSE: ANET ) to come down before buying the stock. Cramer likes NVIDIA (NASDAQ: NVDA ). He loves ...

  • 3 Top Value Stocks to Buy Right Now
    Motley Fool4 days ago

    3 Top Value Stocks to Buy Right Now

    These value stocks may not remain undervalued for long, so you might want to check them out now.

  • Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
    Zacks4 days ago

    Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

    Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

  • Barrons.com9 days ago

    What Alcon’s Spinoff Can Teach Bausch Health

    The spinoff provides a valuable framework to value Bausch Health’s Bausch+Lomb, one which shows the inherent upside to a separation of the businesses, Mizuho analyst Irina Koffler says.

  • 6 Predictable Guru Stocks
    GuruFocus.com10 days ago

    6 Predictable Guru Stocks

    According to the GuruFocus All-in-One Screener, the following companies have high business predictability ratings and a wide margin of safety. The company has a three out of five-star business predictability rank and, according to the discounted cash flow calculator, a 75.47% margin of safety at $25 per share. Warning! GuruFocus has detected 5 Warning Signs with BHC.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Bausch Health Companies Inc.

    Bausch Health Companies Inc NYSE:BHCView full report here! Summary * Perception of the company's creditworthiness is positive and improving * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BHC are favorable with net inflows of $26.88 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator with a strengthening bias over the past 1-month. BHC credit default swap spreads are decreasing and near the lowest level of the last three years, which indicates improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire11 days ago

    Bausch Health Companies Inc. Will Release First-Quarter 2019 Financial Results On May 6

    LAVAL, Quebec , April 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its first-quarter 2019 financial results on Monday, May 6, 2019 . Bausch ...

  • Francis Chou's RRSP Fund Buys 5 in 4th Quarter
    GuruFocus.com14 days ago

    Francis Chou's RRSP Fund Buys 5 in 4th Quarter

    Top buys include Bausch Health, one Buffett Bank and Prem Watsa’s conglomerate

  • Is Bausch Health (BHC) Stock Undervalued Right Now?
    Zacks14 days ago

    Is Bausch Health (BHC) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • All You Need to Know About Bausch (BHC) Rating Upgrade to Buy
    Zacks14 days ago

    All You Need to Know About Bausch (BHC) Rating Upgrade to Buy

    Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • PR Newswire17 days ago

    Bausch + Lomb Announces The U.S. Launch Of LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery

    Shipments to U.S. Pharmaceutical Distributors Begin BRIDGEWATER, N.J. , April 2, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies ...

  • PR Newswire18 days ago

    Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis

    Investigational Treatment Demonstrated Promising Results in Preclinical Studies BRIDGEWATER, N.J. , April 1, 2019 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty ...

  • Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?
    Zacks22 days ago

    Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?

    Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.

  • Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
    Zacks23 days ago

    Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

    Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

  • Analysts Reduce Target Price for Bausch Health Companies in March
    Market Realist24 days ago

    Analysts Reduce Target Price for Bausch Health Companies in March

    What Analysts Think about These Generic Pharmaceutical StocksAnalysts’ recommendations and target price Wall Street analysts expect an upside potential of 24.28% for Bausch Health Companies (BHC) based on the company’s closing price on March 22.

  • Merck Stock Set to Test 18-Year Resistance
    Investopedia24 days ago

    Merck Stock Set to Test 18-Year Resistance

    Merck stock has cleared the final harmonic barrier ahead of a long-awaited test at 2000's all-time high.

  • Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?
    Zacks28 days ago

    Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?

    Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Bausch Health Shows Again It's Among Most Divisive Stocks
    Bloomberglast month

    Bausch Health Shows Again It's Among Most Divisive Stocks

    Analysts at SunTrust started coverage of the drugmaker with a buy rating Tuesday afternoon, telling investors that “management is doing the right things to strengthen the business” despite a heavy debt load. The next morning, Bank of America Merrill Lynch analyst Jason Gerberry re-started the bank’s coverage with a sell-equivalent rating, citing “fundamental challenges” in the next leg of the company’s recovery. The company has divided Wall Street for years despite bailing on its former identity, Valeant Pharmaceuticals.

  • Benzingalast month

    Bullish Mizuho Says Bausch Health's Long-Term Guidance 'Within Reach'

    Bausch Health Companies Inc’s (NYSE: BHC ) growth drivers will become “more tangible” in 2019, and shares could appreciate as the company continues to demonstrate good execution, according to Mizuho Securities. ...

  • The Wall Street Journallast month

    [$$] Synergy Pharma Bankruptcy Plan Cleared for Creditor Poll

    Inc. won court permission to move forward with the second phase of its bankruptcy, winding down what remains of the company following the sale of its assets. In the U.S. Bankruptcy Court in New York Tuesday, Judge James Garrity Jr. approved a blueprint of the company’s wind-down plan, which will soon be sent out to creditors for a vote. Court papers show creditors have until April 11 to cast their ballots. Synergy hopes to win final approval of the plan, which splits the remaining sale proceeds between junior and senior lenders, at another hearing scheduled for April 23. Under the plan, unsecured creditors are guaranteed to take home at least $13 million as well as a chance to share in the proceeds resulting from future lawsuits.

  • Did Changing Sentiment Drive Bausch Health Companies’s (NYSE:BHC) Share Price Down A Painful 83%?
    Simply Wall St.last month

    Did Changing Sentiment Drive Bausch Health Companies’s (NYSE:BHC) Share Price Down A Painful 83%?

    Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. For example,Read More...

  • Is Bausch Health Companies (BHC) a Great Stock for Value Investors?
    Zackslast month

    Is Bausch Health Companies (BHC) a Great Stock for Value Investors?

    Is Bausch Health Companies (BHC) a great pick from the value investor's perspective right now? Read on to know more.

  • PR Newswirelast month

    Ortho Dermatologics Launches 2019 Aspire Higher Scholarship Program For Students With Dermatologic Conditions

    LAVAL, Quebec, March 11, 2019 /PRNewswire/ -- Ortho Dermatologics, one of the largest prescription dermatology health care businesses, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced the opening of applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition. "At Ortho Dermatologics, our passion for dermatology is fueled by our understanding of the tremendous impact the profession can have on patients' lives," said Bill Humphries, president, Ortho Dermatologics.

  • CNW Grouplast month

    SILIQ™ (brodalumab) now covered by the RAMQ in Quebec

    SILIQ™ (brodalumab) now covered by the RAMQ in Quebec